Cancer has one of the highest mortality rates of all diseases worldwide. In Japan too it is the number one cause of death, and naturally, there is an urgent need for new drugs. In 1983 Otsuka established the Fujii Memorial Research Institute (originally the Biwako Research Institute), and has been engaged in anti-cancer drug research ever since, aspiring to help cancer patients worldwide. Today, we are providing new treatment options, especially for those suffering from blood cancers.
In 2008, Otsuka Pharmaceutical acquired the entire business built around the only drug for the conditioning regimen prior to hematopoietic progenitor cell transplantation approved by the U.S. Food and Drug Administration (FDA) and rolled out the business globally. As a pre-treatment prior to hematopoietic progenitor cell transplantation carried out as a part of treatment for all forms of blood cancer, this drug is contributing to patients as a necessary drug that ranks alongside radiation therapy. In 2010, we entered an alliance with Bristol-Myers Squibb in Japan, the US, and Europe to co-promote a therapeutic drug for chronic myelogenous leukemia (CML).